在肥胖患者中进行腹腔透析的管理
Shweta Bansal1,2, Rajeev Nararyan3
1Division of Nephrology, Department of Medicine, University of Texas Health San Antonio.
Current opinion in nephrology and hypertension
|October 24, 2025
概括
肥胖不会增加患有腹膜透析 (PD) 患者的并发症. 谨慎的管理允许有效的PD治疗肥胖患者,与血液透析结果相比较.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 减肥医学 减肥医学
背景情况:
- 末期脏病 (ESKD) 和肥胖症的增加带来了医疗保健方面的挑战.
- 尽管有家庭透析的好处,但对肥胖患者的腹膜透析 (PD) 使用是谨慎的.
研究的目的:
- 审查相关问题,并提供基于证据的指导方针,用于肥胖患者的PD.
- 评估PD在肥胖个体中的安全性和有效性.
主要方法:
- 对当代腹膜透析队伍的分析.
- 审查导管安置和退出地点选择的技术进步.
- 对调整后的体重进行评估,以估计溶液清除率.
- 增量透析和Icodextrin使用的评估.
- 对PD模式和肥胖症结局的最新证据的审查.
主要成果:
- 在接受PD的肥胖患者中,与正常体重患者相比,与导管相关的并发症并不高.
- 技术进步确保通过皮肤放置的导管具有良好的结果.
- 精心放置的出口点可以防止肥胖PD患者感染.
- 调整的体重有助于准确估计溶液的分布和清除.
- 腹膜透析模式不会改变肥胖对移植或生存的影响.
结论:
- 在透析患者中,与肥胖相关的不良结果与血液透析和腹膜透析相似.
- 与血液透析相比,肥胖症在PD中并不明显.
- 周周透析可以有效地给肥胖患者提供,只要谨慎管理.
- 肥胖不应该是腹膜透析的禁忌.
相关概念视频
Peritoneal Dialysis III: Nursing Management
649
Peritoneal dialysis, or PD, utilizes the peritoneal membrane as a filter to eliminate excess fluid and waste products. Effective nursing management is essential for ensuring patient safety, preventing complications, and promoting optimal function of the peritoneal dialysis process.Assessment and MonitoringNurses must thoroughly assess the patient before, during, and after each dialysis session. Regular monitoring includes vital signs, daily weight, fluid intake and output, and laboratory values...
649
Drug Dosing: Obese Patients
218
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
218
Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications
526
Peritoneal dialysis (PD) is a medical process that removes waste products and excess fluid from the body using the peritoneal membrane as a natural filter.Peritoneal Dialysis MethodsSeveral methods can be used for peritoneal dialysis, including Acute Intermittent Peritoneal Dialysis, Continuous Ambulatory Peritoneal Dialysis, and Automated Peritoneal Dialysis, also known as Continuous Cyclic Peritoneal Dialysis.Acute Intermittent Peritoneal Dialysis (AIPD) is used for patients with uremic...
526
Peritoneal Dialysis I: Introduction and Procedure
2.3K
Peritoneal dialysis (PD) is a procedure that facilitates the exchange of solutes, waste products, electrolytes, and excess fluid between the blood in the peritoneal capillaries and a dialysis solution introduced into the peritoneal cavity.Principles of Peritoneal Dialysis (PD)Diffusion: Waste products such as urea and electrolytes move from high concentrations in the blood to low concentrations in the dialysate across the peritoneal membrane. This mechanism is driven by the concentration...
2.3K
Hemodialysis III: Nursing Management
733
The nursing management of a patient undergoing hemodialysis includes several critical steps, starting with a thorough assessment before the procedure.Before the Hemodialysis ProcedureFirst, record the patient's vital signs—blood pressure, heart rate, respiratory rate, and temperature—to establish a baseline. This baseline is essential for detecting conditions such as hypotension that could impact the patient's response to dialysis. Document the patient's pre-dialysis weight, as this...
733
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
245
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
245


